Oxford Biomedica (OXB) Competitors

Oxford Biomedica (LON:OXB) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.

Which has stronger earnings & valuation, OXB or ERGO?

Ergomed has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£98.31M	3.29	-£143.51M	-£134.59	-2.26
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Do analysts recommend OXB or ERGO?

Oxford Biomedica currently has a consensus price target of GBX 380, suggesting a potential upside of 24.79%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is OXB or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -145.98%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-145.98%	-202.50%	-12.67%
Ergomed	9.87%	18.08%	10.16%

Which has more volatility and risk, OXB or ERGO?

Oxford Biomedica has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in OXB or ERGO?

64.1% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 21.2% of Oxford Biomedica shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer OXB or ERGO?

Oxford Biomedica received 117 more outperform votes than Ergomed when rated by MarketBeat users. However, 75.63% of users gave Ergomed an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Oxford Biomedica	Outperform Votes 359 66.73%	Underperform Votes 179 33.27%
Ergomed	Outperform Votes 242 75.63%	Underperform Votes 78 24.38%

Does the media prefer OXB or ERGO?

In the previous week, Oxford Biomedica had 2 more articles in the media than Ergomed. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Ergomed. Oxford Biomedica's average media sentiment score of 0.63 beat Ergomed's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Biomedica	Positive
Ergomed	Neutral

Summary

Ergomed beats Oxford Biomedica on 9 of the 16 factors compared between the two stocks.